Royalty Pharma plc
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Royalty Pharma plc's yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 6% in 3 years; of every extra $100 of sales, $516 became extra profit. Higher than 94% of Healthcare companies in United States.
- Profit Cash Ratio: Over the last 3 years, every $100 of reported profit came with $298 of operating cash. Higher than 87% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$298Over the last 3 years, every $100 of reported profit came with $298 of operating cash.
Higher than 87% of Healthcare companies in United States.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Less steady than 51% of Healthcare companies in United States.
Growth Efficiency Ratio
$516Sales grew 6% in 3 years; of every extra $100 of sales, $516 became extra profit.
Higher than 94% of Healthcare companies in United States.
Asset Productivity Ratio
+6% / +17%In 3 years sales changed by +6% while total assets changed by +17%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
6.6×Debt due within a year is covered 6.6 times by its yearly operating cash.
Higher than 82% of Healthcare companies in United States.
Cash Cushion Ratio
−20%Debt, after subtracting cash, equals 20% of its market value (net debt).
Lower than 84% of Healthcare companies in United States.
Tangible Assets Ratio
95%Of every $100 the company owns, $95 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 73% of Healthcare companies in United States.
Tangible Net Worth Ratio
86%Of every $100 of net worth, $86 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 67% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Royalty Pharma plc owes $0.51 for every $1 it owns. Net profit fell 10% in the year to Dec 2025, and grew 162% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
34.0Investors pay $34.0 for every $1 of Royalty Pharma plc's yearly profit, higher than 62% of Healthcare companies in United States.
P/B ratio
5.40The share price is 5.40 times Royalty Pharma plc's book value per share, higher than 74% of Healthcare companies in United States.
Market cap
$36.9 BThe total market value of all of Royalty Pharma plc's shares at today's price (share price × number of shares), larger than 95% of Healthcare companies in United States. PosiCap size class: Tito Cap.
Net worth (book value)
$6.8 BWhat Royalty Pharma plc would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$11.82Net worth divided by the number of shares. The share price of $63.86 is 5.4 times this, which is the P/B above.
Return on equity (ROE)
14.0%Royalty Pharma plc earned 14.0% on its shareholders' money over the last year, higher than 86% of Healthcare companies in United States.
Owes vs Owns
0.51×Royalty Pharma plc owes $0.51 for every $1 it owns (moderate), higher than 56% of Healthcare companies in United States.
Dividend yield
1.47%Royalty Pharma plc pays 1.47% of its share price as dividends a year, higher than 62% of dividend-paying Healthcare companies in United States.
Revenue growth
+5%Revenue rose 5% in the year to Dec 2025, and grew 2% a year on average over 3 years.
Profit growth
-10%Net profit fell 10% in the year to Dec 2025, and grew 162% a year on average over 3 years.
Profit margin
32.4%Royalty Pharma plc keeps $32 of every $100 of revenue as net profit.
Cash quality
3.2×Cash from Royalty Pharma plc's business was 3.2× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
5.1×Royalty Pharma plc's operating profit covered its interest costs 5.1 times in the year to Dec 2025.
Cash vs debt
Net debtRoyalty Pharma plc had $7.5 B more debt than cash (net debt) at Dec 2025.
Questions
What is Royalty Pharma plc's P/E ratio?
Investors pay $34.0 for every $1 of Royalty Pharma plc's yearly profit, higher than 62% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Royalty Pharma plc: $36.9 B ÷ $6.8 B (30 Jun 2026) = 5.4.
What is Royalty Pharma plc's return on equity?
Royalty Pharma plc earned 14.0% on its shareholders' money over the last year, higher than 86% of Healthcare companies in United States.
How much does Royalty Pharma plc owe compared with what it owns?
Royalty Pharma plc owes $0.51 for every $1 it owns (moderate), higher than 56% of Healthcare companies in United States.
Does Royalty Pharma plc pay a dividend?
Yes. Royalty Pharma plc pays 1.47% of its share price as dividends a year, higher than 62% of dividend-paying Healthcare companies in United States.
Is Royalty Pharma plc's revenue growing?
Revenue rose 5% in the year to Dec 2025, and grew 2% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.